Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546700 | 0.81 | ALDH1A1 (0.36) | ALDH1A1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL23526090 | 0.80 | PDE5A (0.38) | ALDH1A1 | |
| SCHEMBL29945835 | 0.80 | PDE5A (0.38) | ALDH1A1 | |
| SCHEMBL23526292 | 0.73 | NT5E (0.45) | — | |
| SCHEMBL4115923 | 0.73 | DYRK1A (0.44) | ALDH1A1CYP1A2POLBCYP2C19 | |
| SCHEMBL25838975 | 0.73 | ALDH1A1 (0.34) | ALDH1A1POLB | |
| SCHEMBL10077986 | 0.72 | GOT1 (0.46) | ALDH1A1POLB | |
| SCHEMBL30327770 | 0.65 | KDM4E (0.41) | — | |
| SCHEMBL28961833 | 0.64 | PDE5A (0.48) | — | |
| SCHEMBL23525930 | 0.63 | SOS1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | ALDH1A1 3260/4885CYP1A2 4781/4885POLB 3766/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | ALDH1A1 3367/4885CYP1A2 4753/4885POLB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.